Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2000 Jan 3;191(1):147–156. doi: 10.1084/jem.191.1.147

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2000 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Phagocytosis of gram-positive bacteria by TMφ from MSR-A^−/− and MSR-A^+/+ mice. Macrophages were prepared, and phagocytosis was measured as described in Materials and Methods. (A) Phagocytosis of various fluorescently labeled gram-positive bacteria and of zymosan particles by TMφ from MSR-A^−/− or MSR-A^+/+ mice. (B) Phagocytosis of various fluorophore-labeled live gram-positive bacteria in serum-free buffer, with or without Ca²⁺, Mg²⁺, or LTA, by TMφ from MSR-A^+/+ mice. (C) Phagocytosis of S. aureus (Cowan I) by TMφ from MSR-A^+/+ mice in the absence or presence of various SR-AI/II ligands: polyguanylic acid (polyG, 0.5 mg/ml), polyinosinic acid (polyI, 0.5 mg/ml), fucoidan (0.5 mg/ml), LTA (1.0 mg/ml), or polycytidylic acid (polyC, 0.5 mg/ml) in the presence of an RNase inhibitor (10 U/ml). (D) Phagocytosis of various gram-positive bacteria and of zymosan particles by TMφ from MSR-A^+/+ mice in the presence of the anti–SR-AI/II antibody 2F8, or an isotype-matched control antibody (EM-34.1). (E) Phagocytosis of S. aureus (Cowan I) by TMφ from MSR-A^+/+ mice in the presence of various concentrations of 2F8 or LTA. All data represent the mean of six to eight experiments.

Phagocytosis of gram-positive bacteria by TMφ from MSR-A^−/− and MSR-A^+/+ mice. Macrophages were prepared, and phagocytosis was measured as described in Materials and Methods. (A) Phagocytosis of various fluorescently labeled gram-positive bacteria and of zymosan particles by TMφ from MSR-A^−/− or MSR-A^+/+ mice. (B) Phagocytosis of various fluorophore-labeled live gram-positive bacteria in serum-free buffer, with or without Ca²⁺, Mg²⁺, or LTA, by TMφ from MSR-A^+/+ mice. (C) Phagocytosis of S. aureus (Cowan I) by TMφ from MSR-A^+/+ mice in the absence or presence of various SR-AI/II ligands: polyguanylic acid (polyG, 0.5 mg/ml), polyinosinic acid (polyI, 0.5 mg/ml), fucoidan (0.5 mg/ml), LTA (1.0 mg/ml), or polycytidylic acid (polyC, 0.5 mg/ml) in the presence of an RNase inhibitor (10 U/ml). (D) Phagocytosis of various gram-positive bacteria and of zymosan particles by TMφ from MSR-A^+/+ mice in the presence of the anti–SR-AI/II antibody 2F8, or an isotype-matched control antibody (EM-34.1). (E) Phagocytosis of S. aureus (Cowan I) by TMφ from MSR-A^+/+ mice in the presence of various concentrations of 2F8 or LTA. All data represent the mean of six to eight experiments.